IL123601A - Pharmacy preparations containing epinephrine for the treatment of pain - Google Patents

Pharmacy preparations containing epinephrine for the treatment of pain

Info

Publication number
IL123601A
IL123601A IL12360196A IL12360196A IL123601A IL 123601 A IL123601 A IL 123601A IL 12360196 A IL12360196 A IL 12360196A IL 12360196 A IL12360196 A IL 12360196A IL 123601 A IL123601 A IL 123601A
Authority
IL
Israel
Prior art keywords
epinastine
medicament
pain
blocker
nsaid
Prior art date
Application number
IL12360196A
Other languages
English (en)
Hebrew (he)
Other versions
IL123601A0 (en
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of IL123601A0 publication Critical patent/IL123601A0/xx
Publication of IL123601A publication Critical patent/IL123601A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
IL12360196A 1995-11-14 1996-11-13 Pharmacy preparations containing epinephrine for the treatment of pain IL123601A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19542281A DE19542281C2 (de) 1995-11-14 1995-11-14 Verwendung von Epinastin für die Behandlung der Migräne
PCT/EP1996/004957 WO1997017971A1 (de) 1995-11-14 1996-11-13 Verwendung von epinastin für die behandlung von schmerzen

Publications (2)

Publication Number Publication Date
IL123601A0 IL123601A0 (en) 1998-10-30
IL123601A true IL123601A (en) 2002-12-01

Family

ID=7777343

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12360196A IL123601A (en) 1995-11-14 1996-11-13 Pharmacy preparations containing epinephrine for the treatment of pain

Country Status (32)

Country Link
US (1) US5942503A (et)
EP (1) EP0861081B1 (et)
JP (2) JP4264850B2 (et)
KR (1) KR100435611B1 (et)
CN (1) CN1104242C (et)
AR (1) AR004321A1 (et)
AT (1) ATE213160T1 (et)
AU (1) AU706112B2 (et)
BG (1) BG62511B1 (et)
BR (1) BR9611502A (et)
CA (1) CA2232008C (et)
CO (1) CO4770978A1 (et)
CZ (1) CZ290115B6 (et)
DE (2) DE19542281C2 (et)
DK (1) DK0861081T3 (et)
EE (1) EE03512B1 (et)
ES (1) ES2171746T3 (et)
HK (1) HK1015280A1 (et)
HU (1) HU225759B1 (et)
IL (1) IL123601A (et)
NO (1) NO982172L (et)
NZ (1) NZ322467A (et)
PL (1) PL186615B1 (et)
PT (1) PT861081E (et)
RO (1) RO118373B1 (et)
RU (2) RU2238733C2 (et)
SK (1) SK61398A3 (et)
TR (1) TR199800853T2 (et)
TW (1) TW575423B (et)
UY (1) UY24354A1 (et)
WO (1) WO1997017971A1 (et)
ZA (1) ZA969520B (et)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
DE69922688T2 (de) * 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
AU3596500A (en) * 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
DE19958460A1 (de) * 1999-12-03 2001-06-07 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Epinastine-Hydrochlorid in der hochschmelzenden Kristallmodifikation
JP2002087963A (ja) * 2000-09-08 2002-03-27 Nippon Boehringer Ingelheim Co Ltd 直接打錠により製造されたエピナスチン含有錠剤
US20030104017A1 (en) * 2001-10-26 2003-06-05 Boehringer Ingelheim International Gmbh Epinastine formulation for oral administration
DE10152973A1 (de) * 2001-10-26 2003-05-08 Boehringer Ingelheim Int Neue trockene und wässrige Epinastin-Sirup-Formulierung
BR0313175A (pt) * 2002-08-02 2005-06-14 Boehringer Ingelheim Int Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina
EP1575566B1 (en) 2002-12-26 2012-02-22 Pozen, Inc. Multilayer dosage forms containing naproxen and triptans
EP1452177A1 (en) * 2003-02-27 2004-09-01 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
KR20080034916A (ko) * 2005-07-08 2008-04-22 센주 세이야꾸 가부시키가이샤 에피나스틴을 포함하는 경피 흡수 안과 제제
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
WO2007110380A1 (en) * 2006-03-25 2007-10-04 Boehringer Ingelheim International Gmbh Insect bite relief preparation comprising epinastine
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
EP1875899A1 (en) * 2006-06-29 2008-01-09 Laboratorios Del Dr. Esteve, S.A. Use of 5HT7 receptor agonists for the treatment of pain
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
RU2464984C2 (ru) * 2007-11-22 2012-10-27 Общество с ограниченной ответственностью "МС-Вита" Нестероидное противовоспалительное лекарственное средство
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9132119B2 (en) * 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
EP3041506B1 (en) * 2013-09-02 2022-12-14 The University of Melbourne A method of treatment
CN105708840A (zh) * 2014-12-01 2016-06-29 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀组合物
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102041389B1 (ko) 2017-12-12 2019-11-27 (주)프론트바이오 N-(9,13b-디하이드로-1H-디벤조[c,f]이미다조[1,5-a]아제핀-3-일)-2-하이드록시벤즈아미드 및 2-((9,13b-디하이드로-1H-디벤조[c,f]이미다조[1,5-a]아제핀-3-일) 카바모일)페닐 아세테이트의 화합물, 이의 제조방법 및 이를 포함하는 항염증 및 진통제 조성물
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
JP6963651B2 (ja) * 2020-04-16 2021-11-10 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
JP7118579B1 (ja) 2020-04-16 2022-08-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性組成物
CN115448927A (zh) * 2022-10-20 2022-12-09 重庆瑞泊莱医药科技有限公司 一种氢溴酸依匹斯汀晶型ii及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung

Also Published As

Publication number Publication date
CO4770978A1 (es) 1999-04-30
CZ290115B6 (cs) 2002-06-12
CZ149898A3 (cs) 1998-10-14
TR199800853T2 (xx) 1998-09-21
MX9803206A (es) 1998-09-30
DE19542281C2 (de) 1997-12-04
CN1104242C (zh) 2003-04-02
NO982172D0 (no) 1998-05-13
HK1015280A1 (en) 1999-10-15
PL326653A1 (en) 1998-10-12
RU2217144C2 (ru) 2003-11-27
UY24354A1 (es) 2001-10-25
DK0861081T3 (da) 2002-05-27
JP4850880B2 (ja) 2012-01-11
RO118373B1 (ro) 2003-05-30
ATE213160T1 (de) 2002-02-15
NO982172L (no) 1998-05-13
WO1997017971A1 (de) 1997-05-22
ES2171746T3 (es) 2002-09-16
DE59608738D1 (de) 2002-03-21
SK61398A3 (en) 1998-09-09
EP0861081A1 (de) 1998-09-02
DE19542281A1 (de) 1997-05-15
EE03512B1 (et) 2001-10-15
AR004321A1 (es) 1998-11-04
PL186615B1 (pl) 2004-02-27
BG62511B1 (bg) 2000-01-31
KR19990067527A (ko) 1999-08-25
EP0861081B1 (de) 2002-02-13
IL123601A0 (en) 1998-10-30
AU7623096A (en) 1997-06-05
AU706112B2 (en) 1999-06-10
PT861081E (pt) 2002-06-28
EE9800158A (et) 1998-12-15
CA2232008A1 (en) 1997-05-22
KR100435611B1 (ko) 2005-01-13
BG102408A (en) 1998-12-30
NZ322467A (en) 2000-01-28
CN1202111A (zh) 1998-12-16
TW575423B (en) 2004-02-11
HU225759B1 (en) 2007-08-28
CA2232008C (en) 2004-01-06
JP2000500446A (ja) 2000-01-18
HUP9903489A2 (hu) 2000-03-28
JP2009019050A (ja) 2009-01-29
ZA969520B (en) 1997-05-14
US5942503A (en) 1999-08-24
RU2238733C2 (ru) 2004-10-27
BR9611502A (pt) 1999-03-02
JP4264850B2 (ja) 2009-05-20
HUP9903489A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
US5942503A (en) Use of Epinastine for the treatment of pain
AU633762B2 (en) 5ht-3 antagonist for the prevention or reduction of dependence
US5198459A (en) Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
EP0591434A1 (en) Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
JPH11501282A (ja) コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体
US20150258113A1 (en) Use of ibogaine for the treatment of pain
PT92799B (pt) Utilizacao de um agonista parcial de glicina b, nomeadamente um composto amino-isoxazolidina, para a preparacao de um medicamento empregue como antipsicotico e processo para a preparacao de uma composicao farmaceutica contendo o referido agonista
EP0306345B1 (en) 2-alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity
Mellick et al. Cluster headache management with methylphenidate (Ritalin)
CN109562180B (zh) 组胺-3受体反向激动剂、乙酰胆碱酯酶抑制剂和nmda受体拮抗剂的三重组合产品
US5519044A (en) Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
EP0071563B1 (en) Trans-dihyldrolisuride antipsychotic
EP0591395A1 (en) Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
MXPA98003206A (en) Employment of epinastin for the treatment of dolo
GB2240476A (en) Use of 5HT-3 antagonist for preventing or reducing dependence
JPS61191615A (ja) パーキンソン病またはパーキンソン症候群の治療用医薬組成物
Naylor et al. Mechanisms and Control of Emesis. Eds AL Bianchi, L. Grélot, AD Miller, GL King. Colloque INSERM/John Libbey Eurotext Ltd.© 1992, Vol. 223, pp. 115-127

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees